Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	165668-41-7
Formula :	C₁₄H₁₂ClN₃O₄S₂
M.W :	385.85
SMILES Code :	O=S(C1=CC=C(S(=O)(N)=O)C=C1)(NC2=CC=CC3=C2NC=C3Cl)=O
Synonyms :	E 7070
MDL No. :	MFCD00945325
InChI Key :	SETFNECMODOHTO-UHFFFAOYSA-N
Pubchem ID :	216468

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319
Precautionary Statements:	P305+P351+P338

LP-1	20 μM	48 hours	Inhibited MM cell proliferation and induced apoptosis	Blood Adv. 2025 Apr 22;9(8):1991-2005
MM.1S	20 μM	48 hours	Inhibited MM cell proliferation and induced apoptosis	Blood Adv. 2025 Apr 22;9(8):1991-2005
H929	20 μM	48 hours	Inhibited MM cell proliferation and induced apoptosis	Blood Adv. 2025 Apr 22;9(8):1991-2005
IMR-32	5 µM	16 h	To assess the impact of Indisulam on cell cycle and metabolism-related proteins. Results showed significant decreases in CDK4 and TYMS protein levels.	Nat Commun. 2022 Mar 16;13(1):1380
KELLY	1 or 10 µM	0.5–24 h	To validate RBM39 degradation induced by Indisulam. Western blot analysis confirmed RBM39 degradation.	Nat Commun. 2022 Mar 16;13(1):1380
IMR-32	5 µM	6 h	To evaluate the selective degradation of RBM39 by Indisulam. Results showed a significant reduction in RBM39 abundance (~9-fold).	Nat Commun. 2022 Mar 16;13(1):1380
B16-F10 cells	1μM	96 hours	Evaluate the effect of Indisulam on tumor cell growth, results showed inhibition of cell growth after drug treatment	Cell. 2021 Jul 22;184(15):4032-4047. e31
BE2C	250 nM	72 hours	To evaluate the effect of Indisulam on RBM39 degradation, results showed that Indisulam induced dose-dependent reduction of RBM39.	Sci Adv. 2021 Nov 19;7(47):eabj5405
HuCCT1 cells	10 μM	48 hours	To evaluate the effect of Indisulam on CCA cell growth, results showed that Indisulam significantly inhibited cell proliferation and colony formation ability	Cell Mol Gastroenterol Hepatol. 2025;19(1):101404
CCLP1 cells	10 μM	48 hours	To evaluate the effect of Indisulam on CCA cell growth, results showed that Indisulam significantly inhibited cell proliferation and colony formation ability	Cell Mol Gastroenterol Hepatol. 2025;19(1):101404
Jurkat	5 μM	48 hours	To evaluate the antitumor effects of Indisulam on T-ALL cells. Results showed that Indisulam significantly inhibited cell proliferation, promoted apoptosis, and interfered with cell cycle progression.	J Exp Clin Cancer Res. 2024 Jul 24;43(1):205
J.gamma1	1 μM	48 hours	To evaluate the antitumor effects of Indisulam on T-ALL cells. Results showed that Indisulam significantly inhibited cell proliferation, promoted apoptosis, and interfered with cell cycle progression.	J Exp Clin Cancer Res. 2024 Jul 24;43(1):205

Mice	Neuroblastoma xenograft model	Intravenous injection	25 mg/kg	5 days on and 2 days off for two weeks	To evaluate the antitumor effect of Indisulam in vivo, results showed that Indisulam induced an initial complete response in all models, but the time to relapse in neuroblastoma was significantly longer compared to other models.	Sci Adv. 2021 Nov 19;7(47):eabj5405
NSG immunodeficient mice	Subcutaneously injected with SUIT2 or A549 cells	Retro-orbital injection	40 mg/kg	8 days for SUIT2 cells and 5 days for A549 cells	Indisulam significantly inhibited tumor growth of SUIT2 and A549 cells, with a more pronounced effect on SUIT2 cells.	Nat Commun. 2021 Jul 13;12(1):4288
NCr Foxnnu mice	IMR-32 xenograft model	Intravenous	25 mg/kg	8 consecutive days	To evaluate the antitumor efficacy of Indisulam in vivo. Results showed complete tumor regression without relapse.	Nat Commun. 2022 Mar 16;13(1):1380
Mice	B16-F10 tumor model	Intravenous injection	25 mg/kg	5 days per week, continuous treatment	Evaluate the inhibitory effect of Indisulam on tumor growth, results showed significant tumor growth inhibition and enhanced efficacy of immune checkpoint blockade therapy	Cell. 2021 Jul 22;184(15):4032-4047. e31
NOD/SCID mice	Subcutaneous xenograft model	Intraperitoneal injection	15 mg/kg	3 times per week for a total of 7 times	To evaluate the inhibitory effect of Indisulam alone or in combination with MS177 on CCA tumor growth, results showed that combination therapy significantly inhibited tumor growth	Cell Mol Gastroenterol Hepatol. 2025;19(1):101404
NOD scid gamma (NSG) mice	T-ALL xenograft model	Intraperitoneal injection	12.5 mg/kg	Once daily for 5 days on and 2 days off, repeated twice	To evaluate the antitumor effects of Indisulam on T-ALL in vivo. Results showed that Indisulam significantly inhibited tumor growth, prolonged survival, and had no significant toxic side effects.	J Exp Clin Cancer Res. 2024 Jul 24;43(1):205
NOG mice	Subcutaneous H929 tumor model	Intraperitoneal injection	10 mg/kg	9 consecutive days	Significantly reduced tumor volume	Blood Adv. 2025 Apr 22;9(8):1991-2005

{[proInfo.proName]}

CAS No.: 165668-41-7

{[proInfo.proName]}

CAS No.: 165668-41-7

Alternative Products

Product Details of Indisulam

Safety of Indisulam

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03485950	Other Infectious Diseases	Phase 2	Recruiting	May 2019	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact iraad@mdanderson.org Less <<
NCT00165867	Colorectal Cancer	Phase 2	Completed	-	France ... More >> Hôpitaux Civils de Colmar Colmar, France, F- 68024 CRLC Val d'Aurelle Montpellier, France, F-34298 Centre Antoine Lacassagne Nice, France, F-06189 United Kingdom Aberdeen Royal Infirmary Aberdeen, United Kingdom, AB25 2ZN Beatson Oncology Centre Glasgow, United Kingdom, G11 6NT Cookridge Hospital Leeds, United Kingdom, LS16 6QB Leicester Royal Infirmary Leicester, United Kingdom, LE1 5WW Less <<
NCT00059735	Kidney Neoplasms ... More >> Carcinoma, Renal Cell Adenocarcinoma, Renal Cell Less <<	Phase 2	Completed	-	United States, California ... More >> Sacramento, California, United States, 95817 United States, New York Bronx, New York, United States, 10466 New York, New York, United States, 10021 New York, New York, United States, 10032 France Villejuif Cedex, France, 94805 Less <<
NCT00080197	Breast Neoplasms ... More >> Metastases Less <<	Phase 2	Completed	-	-
NCT01692197	-		Completed	-	-
NCT00165854	Colorectal Cancer (CRC)	Phase 2	Completed	-	France ... More >> Centre Léon Bérard Lyon, France, F-69373 Institut Curie Paris, France, F-75005 Germany Universitätsklinikum der GHS-Essen Essen, Germany, D-45122 Netherlands Netherlands Cancer Institute Amsterdam, Netherlands, 1066 CX Less <<
NCT00014625	Melanoma (Skin)	Phase 2	Completed	-	Austria ... More >> Kaiser Franz Josef Hospital Vienna, Austria, A-1100 Belgium Institut Jules Bordet Brussels, Belgium, 1000 France Centre Jean Perrin Clermont-Ferrand, France, 63011 Centre Leon Berard Lyon, France, 69373 Centre Eugene Marquis Rennes, France, 35064 Germany Medizinische Hochschule Hannover Hannover, Germany, D-30625 Italy Istituto Nazionale per lo Studio e la Cura dei Tumori Naples, Italy, 80131 Norway Norwegian Radium Hospital Oslo, Norway, N-0310 Portugal Instituto Portugues de Oncologia de Francisco Gentil Lisbon, Portugal, 1093 Switzerland Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 United Kingdom Royal Marsden NHS Trust London, England, United Kingdom, SW3 6JJ Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT01692197	Leukemia	Phase 2	Completed	-	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00003981	Unspecified Adult Solid Tumor,... More >> Protocol Specific Less <<	Phase 1	Completed	-	Austria ... More >> Innsbruck Universitaetsklinik Innsbruck, Austria, A-6020 Kaiser Franz Josef Hospital Vienna, Austria, A-1100 Belgium Institut Jules Bordet Brussels, Belgium, B-1000 Ludwig Institute for Cancer Research Brussels, Belgium, B-1200 Universitair Ziekenhuis Antwerpen Edegem, Belgium, B-2650 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Denmark Herlev Hospital - University Hospital of Copenhagen Copenhagen, Denmark, DK-2730 France Centre Jean Perrin Clermont-Ferrand, France, 63011 Centre Leon Berard Lyon, France, 69373 CRLCC Nantes - Atlantique Nantes-Saint Herblain, France, 44805 Institut Claudius Regaud Toulouse, France, 31052 Institut Gustave Roussy Villejuif, France, F-94805 Germany Universitaetsklinikum Essen Essen, Germany, D-45122 Netherlands Vrije Universiteit Medisch Centrum Amsterdam, Netherlands, 1001HV Antoni van Leeuwenhoekhuis Amsterdam, Netherlands, 1066 CX Academisch Ziekenhuis Groningen Groningen, Netherlands, 9700 RB University Medical Center Nijmegen Nijmegen, Netherlands, NL-6500 HB Erasmus University Medical Center Rotterdam, Netherlands, 3008 EA Norway Norwegian Radium Hospital Oslo, Norway, N-0310 Switzerland University Hospital Basel, Switzerland, CH-4031 Inselspital, Bern Bern, Switzerland, CH-3010 Kantonsspital - St. Gallen St. Gallen, Switzerland, CH-9007 United Kingdom Newcastle General Hospital Newcastle Upon Tyne, England, United Kingdom, NE4 6BE Royal Marsden Hospital Sutton, England, United Kingdom, SM2 5PT Ninewells Hospital and Medical School Dundee, Scotland, United Kingdom, DD1 9SY Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT00003976	Unspecified Adult Solid Tumor,... More >> Protocol Specific Less <<	Phase 1	Completed	-	Austria ... More >> Innsbruck Universitaetsklinik Innsbruck, Austria, A-6020 Kaiser Franz Josef Hospital Vienna, Austria, A-1100 Belgium Institut Jules Bordet Brussels, Belgium, 1000 Ludwig Institute for Cancer Research-Brussels Branch Brussels, Belgium, B-1200 Universitair Ziekenhuis Antwerpen Edegem, Belgium, B-2650 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Denmark Herlev Hospital - University Hospital of Copenhagen Herlev, Denmark, DK-2730 France Centre Jean Perrin Clermont-Ferrand, France, 63011 Centre Leon Berard Lyon, France, 69373 CRLCC Nantes - Atlantique Nantes-Saint Herblain, France, 44805 Institut Claudius Regaud Toulouse, France, 31052 Institut Gustave Roussy Villejuif, France, F-94805 Germany Universitaetsklinik und Strahlenklinik - Essen Essen, Germany, D-45122 Klinikum Nurnberg Nuremberg (Nurnberg), Germany, D-90419 Netherlands Antoni van Leeuwenhoekhuis Amsterdam, Netherlands, 1066 CX Academisch Ziekenhuis der Vrije Universiteit Amsterdam, Netherlands, 1117 MB Academisch Ziekenhuis Groningen Groningen, Netherlands, 9713 EZ University Medical Center Nijmegen Nijmegen, Netherlands, NL-6252 HB Rotterdam Cancer Institute Rotterdam, Netherlands, 3075 EA Norway Norwegian Radium Hospital Oslo, Norway, N-0310 Switzerland University Hospital Basel, Switzerland, CH-4031 Inselspital, Bern Bern, Switzerland, CH-3010 Kantonsspital - Saint Gallen Saint Gallen, Switzerland, CH-9007 United Kingdom Newcastle General Hospital Newcastle Upon Tyne, England, United Kingdom, NE4 6BE Ninewells Hospital and Medical School Dundee, Scotland, United Kingdom, DD1 9SY Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 9NQ C.R.C. Beatson Laboratories Glasgow, Scotland, United Kingdom, G61 1BD Less <<
NCT00165880	Metastatic Breast Cancer	Phase 2	Terminated(This study was stop... More >>ped prematurely due to lack of efficacy.) Less <<	-	Germany ... More >> Charite Universitatsmedizin Berlin Berlin, Germany, D-12200 Stadt Kliniken Frankfurt-Hochst Frankfurt, Germany, D-65929 IORC Gmbh Hamburg, Germany, D-22081 Medizinische Klinik und Poliklinik Mainz, Germany, D-55101 Zentrum fur Innere Medizin Hamatologie / Onkologie Stuttgart, Germany, D-70376 Italy Ospedali Ruiniti Bergamo, Italy, I-24128 Ospedale S. Maria Annunzialata Firenze, Italy, I-50011 Ospedale Morgagni-Pierantoni Forli, Italy, I-47100 IST Istituto nazionale per la Ricerca Genova, Italy, I-16132 Palilinico Universitano Palermo, Italy, I-90127 Azienda Ospedaliera Pisana Pisa, Italy, I-56126 A.O. Arciospedate S. Maria Nuova Reggio Emilia, Italy, I-42100 Ospedale San Filippo Neri Roma, Italy, I-00135 Russian Federation Arkhangelsk Regional Clinical Oncology Center Arkhangelsk, Russian Federation, 163045 Chelyabinsk Regional Oncology Center Chelyabinsk, Russian Federation, 454087 Krasnodar City Oncology Center Krasnodar, Russian Federation, 350040 Leningrad Regional Oncology Center Kuzmolovo, Russian Federation, 188663 Hertzen Research Institute of Oncology Moscow, Russian Federation, 125284 Semashko Central Clinical Hospital Moscow, Russian Federation, 129128 Rostov Oncology Research Institute Rostov-on-Don, Russian Federation, 344037 Petrov Research Institute of Oncology St. Petersburg, Russian Federation, 197758 Spain Hospital Universiatio de Guadalajara Guadalajara, Spain, I-19002 Centro Oncologico Regional de Galicia La Coruna, Spain, E-15009 Hospital Unicersaitario de La Princesa Madrid, Spain, E-28006 Centro Oncologico Anderson Internacional Madrid, Spain, E-28033 Hospital Clinico U. Virgen de la Victoria Malaga, Spain, E-29010 Hospital Clinico Universitario Lozano Blesa Zaragoza, Spain, E-50009 Hospital Clinico Universitario Lozano Blesa Zaragoza, Spain, I-19002 United Kingdom Cookridge Hospital Leeds, United Kingdom, LS16 6QB St Bartholomew's Hospital London, United Kingdom, EC1A 7BE Christie Hospital NHS Trust Manchester, United Kingdom, M20 4GJ Mount Vernon Cancer Centre Northwood, United Kingdom, HA1 2RN South West Wales Cancer Institute Swansea, United Kingdom, SA2 8QA Less <<
NCT00060567	Cancer	Phase 1	Completed	-	United States, Massachusetts ... More >> Boston, Massachusetts, United States Less <<
NCT00165594	Gastric Cancer	Phase 1 Phase 2	Terminated(Study was completed... More >>.) Less <<	-	Japan ... More >> Kashiwa, Chiba-prefecture, Japan, 277-0882 Sagamihara-shi, Kanagawa, Japan Takatsuki-shi, Osaka, Japan Sunto-gun, Shizuoka-prefecture, Japan, 411-0934 Chuo-ku, Tokyo, Japan, 104-0045 Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.59mL 0.52mL 0.26mL	12.96mL 2.59mL 1.30mL	25.92mL 5.18mL 2.59mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed